JNJ 26483327
Protein Kinase Inhibitors
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Protein Kinase Inhibitors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VOLITINIB AstraZeneca | Phase 3 | B |
su011248 AstraZeneca | Phase 3 | B |
Sorafenib Sichuan Cancer Hospital and Research Institute | Phase 2 | B |
JYP0322 Guangzhou JOYO Pharma Co., Ltd | Phase 1 | CC |
Carboplatin Blueprint Medicines Corporation | Phase 1 | CC |
Blu-701 Blueprint Medicines Corporation | Phase 1 | CC |
Tigozertinib Blueprint Medicines Corporation | Phase 1 | CC |
Osimertinib Blueprint Medicines Corporation | Phase 1 | CC |
Same molecule, other indications
JNJ 26483327 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →